Cargando…
Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours
Patients with poor and intermediate prognosis metastatic germ-cell tumours (MGCTs) are at a significant risk of relapse after standard platinum-based chemotherapy. Novel treatment regimens are required to improve survival. Dose intense, alternating combinations of drugs with known activity in germ-c...
Autores principales: | Anthoney, D A, McKean, M J, Roberts, J T, Hutcheon, A W, Graham, J, Jones, W, Paul, J, Kaye, S B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409589/ https://www.ncbi.nlm.nih.gov/pubmed/14760371 http://dx.doi.org/10.1038/sj.bjc.6601528 |
Ejemplares similares
-
Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)
por: Cafferty, Fay H., et al.
Publicado: (2020) -
Real-World Study of Cisplatin, Etoposide, and Bleomycin Chemotherapy Regimen in Gestational Trophoblastic Neoplasia
por: Wang, Ming, et al.
Publicado: (2021) -
The Effects of Chemotherapeutic Agents, Bleomycin, Etoposide, and Cisplatin, on Chromatin Remodeling in Male Rat Germ Cells
por: Bagheri-Sereshki, Negar, et al.
Publicado: (2016) -
Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors
por: Nakagawa, Ryunosuke, et al.
Publicado: (2022) -
Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)
por: Dearnaley, D P, et al.
Publicado: (2005)